Kyongbo Pharmaceutical Co., Ltd
214390.KSFinancial Statements
Income Statement (Annual)
Amounts in millions
2024
12/31/2024
Revenue
179
Cost of Revenue
117
Gross Profit
62
Gross Margin
34.5%
Operating Income
8
Operating Margin
4.4%
Net Income
3
Net Margin
1.9%
EPS (Basic)
$0.00
EPS (Diluted)
$0.00
EBITDA
16
EBITDA Margin
9.1%
2023
12/31/2023
Revenue
162
Cost of Revenue
115
Gross Profit
47
Gross Margin
29.2%
Operating Income
4
Operating Margin
2.6%
Net Income
2
Net Margin
1.4%
EPS (Basic)
$0.00
EPS (Diluted)
$0.00
EBITDA
13
EBITDA Margin
8.0%
2022
12/31/2022
Revenue
147
Cost of Revenue
114
Gross Profit
33
Gross Margin
22.6%
Operating Income
1
Operating Margin
0.7%
Net Income
0
Net Margin
0.3%
EPS (Basic)
$0.00
EPS (Diluted)
$0.00
EBITDA
10
EBITDA Margin
6.5%
2021
12/31/2021
Revenue
128
Cost of Revenue
101
Gross Profit
27
Gross Margin
20.7%
Operating Income
-3
Operating Margin
-2.7%
Net Income
-6
Net Margin
-4.4%
EPS (Basic)
$0.00
EPS (Diluted)
$0.00
EBITDA
3
EBITDA Margin
2.5%
2020
12/31/2020
Revenue
161
Cost of Revenue
122
Gross Profit
39
Gross Margin
24.4%
Operating Income
4
Operating Margin
2.6%
Net Income
7
Net Margin
4.4%
EPS (Basic)
$0.00
EPS (Diluted)
$0.00
EBITDA
16
EBITDA Margin
9.9%